Senior Manager, Scientific Communications and Publications
- Employer
- Intellia Therapeutics
- Location
- Cambridge, MA
- Start date
- Aug 27, 2021
View more
- Discipline
- Marketing, Marketing/Corporate Communications
- Required Education
- Masters Degree/MBA
- Position Type
- Full time
- Hotbed
- Genetown
Job Details
Why Join Intellia?
Our mission is to develop curative genome editing treatments that can positively transform the lives of people living with severe and life-threatening diseases.
Beyond our science, we live our four core values: One, Explore, Disrupt, Deliver and feel strongly that you can achieve more at Intellia. We have a single-minded determination to excel and succeed together. We believe in the power of curiosity and pushing boundaries. We welcome challenging thoughts and imagination to develop innovative solutions. And we know that patients are counting on us to make the promise a reality, so we must maintain high standards and get it done.
We want all of our people to go beyond what is possible. We aren’t constrained by typical end rails, and we aren’t out to just “treat” people. We’re all in this for something more. We’re driven to cure and motivated for change. Just imagine the possibilities of what we can do together.
How you will Achieve More with Intellia:
As a critical member of the Investor Relations and Corporate Communications team, the newly-created Senior Manager of Scientific Communications and Publications role is responsible for the strategic planning and execution of high-quality scientific communications deliverables. You will work cross-functionally to drive the planning and production of publications, slide presentations, abstracts, symposia, and other scientific materials.
The Senior Manager of Scientific Communications and Publications ensures that all scientific communications supporting the research, preclinical, and clinical pipeline at Intellia are accurate, compliant, balanced, and of the highest quality. In this role, you will be responsible for driving the cross-functional internal review process for all scientific publications and presentations ensuring compliance with global standards, scientific accuracy, and consistency with Intellia’s corporate communications strategies.
Core responsibilities include:
Design the publication strategy and implementation with guidance and support from the Senior Management team for a variety of therapeutic candidates in preclinical and clinical development
Lead cross-functional publication planning team meetings, including the planning and execution of annual publication planning workshops
Work with cross-functional partners to develop scientific presentations for a variety of audiences, including scientific, medical, and patient organizations including, but not limited to, manuscripts, abstracts, posters, and oral presentations
Manage and facilitate the content review process, including collating reviewer comments and having discussions with authors and reviewers
Work with vendors to ensure projects and deliverables are designed and executed seamlessly and on time
Support content development for patient advocacy initiatives and additional educational resources that align with program objectives
Provide support for key scientific congresses and meetings including conference registration and organizing conference reports for Intellia attendees
Organize training workshops for Intellia scientists (e.g. public speaking, presentation skills)
Mange scientific literature databases utilized by Intellia scientific teams
About You:
We are looking for an experienced scientific communications manager with a minimum of 4 years of prior experience developing and executing medical publications, including medical writing and presentation creation, and 5+ years of total industry experience. Previous scientific communications experience in the pharmaceutical or biotech industry or at a medical communications agency. Additional requirements include the following:
A doctoral degree (Ph.D., PharmD) or master’s degree in a scientific discipline
Strong interpersonal, analytical, and communications skills; ability to incorporate feedback from multiple, diverse stakeholders with variable technical expertise
Outstanding planning and organizational skills; able to balance multiple priorities
Excellent written communication skills, including the ability to translate scientific content for appropriate audiences
Demonstrated ability to effectively work with cross-functional partners, vendors, and external thought leaders
Highly self-motivated, with a track record of excelling in a fast-paced work environment
Prior experience in one or more of the following: cell and nucleic acid therapies, precision medicine, rare diseases, oncology, and immunology
Creative, passionate, and a problem-solver
Able to travel to scientific meetings, as necessary
Meet your future team:
This role will report directly to the Senior Vice President, Investor Relations and Corporate Communications. The team is made up of individuals who bring a range of experience and knowledge, spread across Investor Relations, Corporate Communications, and Scientific Communications. You will join a team of passionate individuals who enjoy working with one another.
The team is currently working virtually with a tentative return to the office in Cambridge, MA slated for January 2022 with some location flexibility expected to continue for the group. Although currently working in a virtual environment, the group has made it a priority to continue to foster a sense of community among the team. This includes virtual happy hours, team all-hands, and more! You can expect to join a hardworking, collaborative environment.
#LI-PD1
EEOC Statement: Intellia believes in a diverse environment, and is committed to equal employment opportunity for all its employees and qualified applicants. We do not discriminate in recruitment, hiring, training, promotion or any other employment practices for reasons of race, color, religion, gender, national origin, age, sexual orientation, marital or veteran status, disability, or any other legally protected status. Intellia will make reasonable accommodations for qualified individuals with known disabilities, in accordance with applicable law.
Company
Many of us pursuing work in the biotechnology industry are inspired by a loved one who is living with a disease or the loss of someone in our community. Rare genetic and oncological and immunological diseases not only affect the people living with often debilitating and life-threatening symptoms, but these disorders also significantly impact their families, friends and caregivers.
Our researchers work tirelessly to harness the genome editing technology CRISPR/Cas9 for human therapeutic use. Jennifer Doudna, an Intellia co-founder, and Emmanuelle Charpentier were awarded the 2020 Nobel Prize in Chemistry for their pioneering work in CRISPR. We at Intellia are humbled to have a hand in making what we believe to be medical history. As a leader in this space, we take this responsibility to patients seriously.
We are employing a modular genome editing platform to create diverse in vivo and ex vivo pipelines, spanning a range of therapeutic indications. Guided by this full-spectrum approach, we are committed to making CRISPR/Cas9-based medicines a reality for patients suffering from genetic diseases and to creating novel engineered cell therapies for various cancers and autoimmune diseases.
Change life stories with genome editing therapies!
Stock Symbol: NTLA
- Website
- http://intelliatx.com/
- Phone
- (857) 285-6200
- Location
-
40 Erie Street
Cambridge
Massachusetts
02139
United States
Get job alerts
Create a job alert and receive personalized job recommendations straight to your inbox.
Create alert